Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


1 Ann Oncol
1 Ann Surg
2 Ann Thorac Surg
6 BMC Cancer
1 Cancer
1 Cancer Res
1 Clin Cancer Res
9 Clin Lung Cancer
1 Int J Cancer
2 Int J Oncol
2 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 Lancet Oncol
1 Nat Rev Cancer
2 PLoS One
1 Thorax

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Oncol

  1. PASTORINO U, Silva M, Sestini S, Sabia F, et al
    Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial.
    Ann Oncol. 2019 Apr 1. pii: 5425325. doi: 10.1093.
    PubMed     Text format     Abstract available

    Ann Surg

  2. YANG CJ, Kumar A, Deng JZ, Raman V, et al
    A National Analysis of Short-term Outcomes and Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Clinical Stage II Non-Small-Cell Lung Cancer.
    Ann Surg. 2019 Mar 26. doi: 10.1097/SLA.0000000000003231.
    PubMed     Text format     Abstract available

    Ann Thorac Surg

  3. MARTIN AN, Kozower BD, Camacho F, Hassinger T, et al
    Disparities in Lung Cancer Screening Availability: Lessons from Southwest, Virginia.
    Ann Thorac Surg. 2019 Apr 2. pii: S0003-4975(19)30429.
    PubMed     Text format     Abstract available

  4. MOHAMMAD Z, Mitchell KG, Nelson DB, Robb C, et al
    Lung Cancer Patient Perceptions of the Value of an Outreach Thoracic Surgical Clinic.
    Ann Thorac Surg. 2019 Mar 27. pii: S0003-4975(19)30415.
    PubMed     Text format     Abstract available

    BMC Cancer

  5. SUMODHEE S, Bondiau PY, Poudenx M, Cohen C, et al
    Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.
    BMC Cancer. 2019;19:305.
    PubMed     Text format     Abstract available

  6. FURUGAKI K, Mochizuki M, Kohno M, Shu S, et al
    Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    BMC Cancer. 2019;19:301.
    PubMed     Text format     Abstract available

  7. YING J, Zhou D, Gu T, Huang J, et al
    Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
    BMC Cancer. 2019;19:288.
    PubMed     Text format     Abstract available

  8. LEE JS, Hur JY, Kim IA, Kim HJ, et al
    Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    BMC Cancer. 2018;18:1236.
    PubMed     Text format     Abstract available

  9. ZANELLI M, Mengoli MC, Del Sordo R, Cagini A, et al
    Intravascular NK/T-cell lymphoma, Epstein-Barr virus positive with multiorgan involvement: a clinical dilemma.
    BMC Cancer. 2018;18:1115.
    PubMed     Text format     Abstract available

  10. CHO YJ, Cho YM, Kim SH, Shin KH, et al
    Clinical analysis of patients with skeletal metastasis of lung cancer.
    BMC Cancer. 2019;19:303.
    PubMed     Text format     Abstract available


  11. Lung cancer: diagnosis and management: summary of updated NICE guidance.
    BMJ. 2019;365:l1514.
    PubMed     Text format    


  12. MORGENSZTERN D, Ko A, O'Brien M, Ong TJ, et al
    Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.
    Cancer. 2019 Apr 1. doi: 10.1002/cncr.32114.
    PubMed     Text format     Abstract available

    Cancer Res

  13. ZHAO J, Feng M, Liu D, Liu H, et al
    Antagonism between HtrA3 and TGF-beta1 Contributes to Metastasis in Non-small-cell Lung Cancer.
    Cancer Res. 2019 Apr 2. pii: 0008-5472.CAN-18-2507.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  14. VENDRELL J, Mazieres J, Senal R, Rouquette I, et al
    Ultra-sensitive EGFR (T790M)detection as an independent prognostic marker for lung cancer patients harboring EGFR (del19)mutations and treated with first-generation TKIs.
    Clin Cancer Res. 2019 Apr 1. pii: 1078-0432.CCR-18-2683.
    PubMed     Text format     Abstract available

    Clin Lung Cancer

  15. NAKAMURA M, Kageyama SI, Niho S, Okumura M, et al
    Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2019 Mar 4. pii: S1525-7304(19)30071.
    PubMed     Text format     Abstract available

  16. VITTORIO A, Sharma R, Siejka D, Bhattarai K, et al
    Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.
    Clin Lung Cancer. 2018;19:e717-e720.
    PubMed     Text format    

  17. ANDERSSON S, Ilonen I, Jarvinen T, Rauma V, et al
    Surgically Treated Unsuspected N2-Positive NSCLC: Role of Extent and Location of Lymph Node Metastasis.
    Clin Lung Cancer. 2018;19:418-425.
    PubMed     Text format     Abstract available

  18. MATSUOKA H, Kimura H, Koba H, Tambo Y, et al
    Nivolumab-induced Limbic Encephalitis with Anti-Hu Antibody in a Patient With Advanced Pleomorphic Carcinoma of the Lung.
    Clin Lung Cancer. 2018;19:e597-e599.
    PubMed     Text format    

  19. FUJIMOTO N, Aoe K, Kozuki T, Oze I, et al
    A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Clin Lung Cancer. 2018;19:e705-e707.
    PubMed     Text format     Abstract available

  20. ZHANG C, Li F, Li J, Xu Y, et al
    Docetaxel Down-Regulates PD-1 Expression via STAT3 in T Lymphocytes.
    Clin Lung Cancer. 2018;19:e675-e683.
    PubMed     Text format     Abstract available

  21. WEI YF, Lim CK, Tsai MS, Huang MS, et al
    Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases.
    Clin Lung Cancer. 2019 Feb 26. pii: S1525-7304(19)30059.
    PubMed     Text format     Abstract available

  22. DING M, Deng L, Yu R, Lu D, et al
    Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.
    Clin Lung Cancer. 2019 Feb 27. pii: S1525-7304(19)30064.
    PubMed     Text format    

  23. SHAABAN SG, Verma V, Choi JI, Shabason J, et al
    Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States.
    Clin Lung Cancer. 2018;19:e685-e692.
    PubMed     Text format     Abstract available

    Int J Cancer

  24. PAN Y, Yuan C, Cheng C, Zhang Y, et al
    Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
    Int J Cancer. 2019;144:290-296.
    PubMed     Text format     Abstract available

    Int J Oncol

  25. ZHANG J, Li J, Li S, Zhou C, et al
    miR802 inhibits the aggressive behaviors of nonsmall cell lung cancer cells by directly targeting FGFR1.
    Int J Oncol. 2019 Mar 29. doi: 10.3892/ijo.2019.4765.
    PubMed     Text format     Abstract available

  26. SUN X, Jia M, Sun W, Feng L, et al
    Functional role of RBM10 in lung adenocarcinoma proliferation.
    Int J Oncol. 2019;54:467-478.
    PubMed     Text format     Abstract available

    Int J Radiat Oncol Biol Phys

  27. GROSSHANS DR, Brown PD
    Chemotherapy Plus Proton or Photon Radiation on a Trial.
    Int J Radiat Oncol Biol Phys. 2018;101:518-519.
    PubMed     Text format    

  28. HURMUZ P, Ozyigit G
    In Regard to Nantavithya et al.
    Int J Radiat Oncol Biol Phys. 2018;101:744-745.
    PubMed     Text format    

    J Clin Oncol

  29. BEZJAK A, Paulus R, Gaspar LE, Timmerman RD, et al
    Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
    J Clin Oncol. 2019 Apr 3:JCO1800622. doi: 10.1200/JCO.18.00622.
    PubMed     Text format     Abstract available

    Lancet Oncol

  30. BAAS P, Burgers S
    Malignant pleural effusions: will PROMISE make its name true?
    Lancet Oncol. 2018;19:853-855.
    PubMed     Text format    

    Nat Rev Cancer

  31. RUDIN CM, Poirier JT, Byers LA, Dive C, et al
    Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
    Nat Rev Cancer. 2019 Mar 29. pii: 10.1038/s41568-019-0133.
    PubMed     Text format     Abstract available

    PLoS One

  32. STANISLAWSKA-SACHADYN A, Borzyszkowska J, Krzeminski M, Janowicz A, et al
    Folate/homocysteine metabolism and lung cancer risk among smokers.
    PLoS One. 2019;14:e0214462.
    PubMed     Text format     Abstract available

  33. ZABECK H, Dienemann H, Hoffmann H, Pfannschmidt J, et al
    Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma.
    PLoS One. 2018;13:e0206132.
    PubMed     Text format     Abstract available


  34. VIS DC, Kelly MM, Lee AG, Gelfand G, et al
    Contralateral recurrence of inflammatory myofibroblastic tumour of the lung 10 years after pneumonectomy.
    Thorax. 2018;73:1089-1090.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.